ScholarIQanswers from OpenAlex & ORCID
Michael F. Press
ResearcherPublications, citations & collaboration network
Michael F. Press is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michael F. Press have?
ScholarIQindexed works
Michael F. Press has 629 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michael F. Press have?
ScholarIQcitation count
Michael F. Press has 55,846 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michael F. Press?
ScholarIQh-index
Michael F. Press has an h-index of 91 in OpenAlex.
What is the i10-index of Michael F. Press?
ScholarIQi10-index
Michael F. Press has an i10-index of 241 in OpenAlex.
What is the ORCID of Michael F. Press?
ScholarIQorcid
The ORCID for Michael F. Press is on the source record.
What is the OpenAlex record for Michael F. Press?
ScholarIQopenalex
The OpenAlex for Michael F. Press is on the source record.
What are the most-cited papers on Michael F. Press?
ScholarIQmost cited works
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis J. Slamon, W. Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, Miguel Martín, Michael F. Press, John R. Mackey, John A. Glaspy, Arlene Chan, Marek Pawlicki, Tamás Pintér, Vicente Valero, Mei-Ching Liu, Guido Sauter, Gϋnter von Minckwitz, F. Visco, Valerie Bée, Marc Buyse, Belguendouz Bendahmane, Isabelle Tabah-Fisch, Mary-Ann Lindsay, A. Riva, John Crown
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
Guido Sauter, James A. Lee, John M.S. Bartlett, Dennis J. Slamon, Michael F. Press
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas
Cindy Wilson, Lillian Ramos, Maria R. Villaseñor, Karl H. Anders, Michael F. Press, Kathy Clarke, Beth Y. Karlan, Jun-Jie Chen, Ralph Scully, David M. Livingston, Robert H. Zuch, Michael H. Kanter, Sylvan Cohen, Frank J. Calzone, Dennis J. Slamon
Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab
R. Mass, Michael F. Press, Steven M. Anderson, Melody Cobleigh, Charles L. Vogel, Noël Dybdal, Grazyna Leiberman, Dennis J. Slamon
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Rosie Bradley, Jeremy Braybrooke, Richard J. Gray, Robert K. Hills, Zulian Liu, Richárd Pető, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, Stewart Anderson, Richard D. Gelber, Luca Gianni, William Jacot, Heikki Joensuu, Alvaro Moreno‐Aspitia, Martine Piccart, Michael F. Press, Edward H. Romond, Dennis J. Slamon, Vera J. Suman, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Frances Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles E. Geyer, M. Spielmann, Pinuccia Valagussa, Kathy S. Albain, Stewart Anderson, R. Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith M. Bliss, Étienne Brain, Lisa Carey, Robert E. Coleman, Jack Cuzick, Nancy E. Davidson, Lucia Del Mastro, Angelo Di Leo, James J. Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, Michael Gnant, Matthew Bidwell Goetz, Pam Goodwin, Pat Halpin-Murphy, Daniel Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P. Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori J. Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Tanja Španić, Joseph A. Sparano, Guenther G. Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Timothy J. Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I. Pritchard